[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-asthma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-asthma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100392893","samba-trial-towards-a-paradigm-shift-in-severe-asthma-management-deep-analysis-of-the-effect-of-submaximal-aerobic-training-100392893",false,"NCT04395937","SAMBA Trial: Towards a Paradigm Shift in Severe Asthma Management: Deep Analysis of the Effect of suBmaximal Aerobic Training","Inclusion Criteria:\n\n* asthmatic patient\n* aged 18- 65 years\n* ACQ \\> 1.5\n* stable background treatment comprising at least one inhaled corticosteroid or an anti-leukotriene\n\nExclusion Criteria:\n\n* IMC \\> 35\n* severe osteoarthritis of the knees and hips\n* unstable angor\n* Severe uncontrolled hypertension","ALL","18 Years","65 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","The effects of regular exercise on asthma control has not yet been well demonstrated.\n\nThe aim of this study is to investigate the impact of submaximal aerobic training on exercise tolerance (VO2max - primary outcome) and a set of secondary outcomes: quality of life, asthma symptoms control, bronchial and systemic inflammatory markers, lung function, bronchial hyperresponsiveness, anxiety and depression and body composition in patients with persistant asthma.",[26],"Chronic Asthma","RECRUITING","2026-04-13",{"date":30,"type":31},"2026-04-14","ACTUAL",{"date":33,"type":31},"2020-09-01",{"date":35,"type":20},"2028-09-01",{"name":37,"class":38},"University of Liege","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":15,"minAge":16,"maxAge":48,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100528671","follow-up-of-spanish-prospective-asthma-and-nasal-polyposis-registry-100528671","NCT06163807","Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry","MEGA","Inclusion Criteria:\n\nFor the general asthma cohort (MEGA):\n\n* Age from 18 to 80 y.o. with asthma with and without nasal polyposis based on GINA guidelines (compatible clinical symptoms+reversibility of at least 12% and 200 mL in FEV1 after the administration of 200-400 μg albuterol\u002Fsalbutamol or positive methacholine test) of several severities attended at participant centres\n* Already in follow-up in MEGA cohort\n* To participate in the study\n* Signed informed consent\n\nInclusion criteria for asthma patients treated with biologics\n\n* Patients from 18 to 80 y.o. with uncontrolled asthma with and without nasal polyposis that fulfil criteria to be treated with biological drugs (Existing treatment with medium-to-high-dose ICS (≥ 250 μg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 μg\u002Fday of fluticasone propionate or equivalent) in combination with a second controller (e.g., LABA, LTRA) for at least 3 months+ airflow limitation- FEV1 \\\u003C80%\u002FFEV1\u002FFVC \\\u003C70+ACQ-5 score ≥ 1.5\u002F ACT \\\u003C 19 at inclusion and\u002For have experience any of the following events on the last year: treatment with systemic steroids\u002F hospitalization or emergency medical care visit for worsening asthma.\n* When planning dupilumab, mepolizumab, benralizumab or reslizumab, biomarker levels, and exacerbation in the previous year will be considered according to the Spanish Ministry of Health recommendations for reimbursement of any biological drug in severe asthma. In the case of Omalizumab allergic asthma and IgE \\> 75 and \\\u003C 1500 UI\n* Patients already in follow-up in the cohort of patients treated with biologics\n* Willing to participate in the study\n* Sign informed consent\n\nExclusion Criteria:\n\n* Exclusion criteria for MEGA COHORT\n\n  * Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function\n  * Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders\n  * Patients participating in other clinical trials\n  * Patients without the capacity to understand the aim of the study\n* Exclusion criteria for asthma patients treated with biologics\n\n  * Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function\n  * Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders\n  * Patients participating in other clinical trials\n  * Patients without the capacity to understand the aim of the study",true,"80 Years",{"count":50,"type":20},1200,"3 Years","OBSERVATIONAL","Primary objective\n\n\\- To study the stability of different phenotypes and endotypes of asthma at 3, 5, and 7 years of follow-up and - in MEGA COHORT and in patients on biologic treatment\n\nSecondary objective(s)\n\n* To study biomarkers variation post-treatment in patients with and without Nasal Polyposis\n* To demonstrate the existence of different subtypes of eosinophils that may be phenotypically and functionally heterogeneous\n* To increase the number of patients in the cohort on biologic treatment to reach at least 900 (400 over the current cohort).",[26],[56,57,58,59,60],"asthma","biologics","biomarkers","nasal polyposis","eosinophils","2026-03-25",{"date":63,"type":31},"2026-03-30",{"date":65,"type":31},"2025-02-01",{"date":67,"type":20},"2026-06-02",{"name":69,"class":38},"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz",8,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":15,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":39},"100539466","telehealth-and-onsite-maintenance-exercise-in-chronic-lung-disease-100539466","NCT06304207","Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease","Comparison of Telehealth and Onsite Supervised Maintenance Exercise Program for Adults With Chronic Lung Disease: A Pilot Randomized Controlled Trial","CLD","Inclusion Criteria:\n\n* All adult patients 40 years and older with physician diagnosed Chronic Lung Disease within 2 months of discharge following completion of a traditional onsite outpatient rehabilitation or physical therapy or exercise program for their condition\n* Able to walk independently with or without mobility devices\n* Able to complete a six-minute walk test at discharge with or without supplemental oxygen maintaining an oxygen saturation at or above 85%\n* Able to follow commands and instructions in the English language\n* Have ability to connect to the internet\n\nExclusion Criteria:\n\n* • Those with significant mobility limitations such as those with a history of stroke, neurological comorbidities such as Parkinson's disease or relapsing multiple sclerosis, or significant degenerative osteoarthritis, or any other joint impairments that compromise ability to walk independently with or without an assistive device.\n\n  * Patients who primarily rely on a wheelchair for mobility\n  * Patients with or without supplemental oxygen who are unable to complete a walking test without a drop in oxygen saturation to below 85% at discharge from traditional outpatient rehabilitation\n  * Patients with baseline hemodynamic compromise, unstable angina, a recent myocardial infarction within a week, uncontrollable atrial fibrillation not managed with medications, advanced stage heart failure (New York Heart Association class 4), or those with mechanical circulatory assist devices for the heart such a ventricular assist device (VADs)\n  * Inability to communicate in the English language","40 Years",{"count":81,"type":20},30,[23],"The goal of this pilot clinical trial is to compare telehealth and onsite supervised maintenance exercise program for adults with Chronic Lung Disease.\n\nThe specific aims of the study are:\n\n* To compare 8-week supervised maintenance program delivered onsite and via tele-rehab with no maintenance for patients with Chronic Lung Disease following discharge from traditional exercise or physical therapy or onsite outpatient rehabilitation programs on clinical outcomes (dyspnea, exercise capacity, physical function, physical activity, and quality of life) at 8 weeks and 4-months post-intervention.\n* To compare the differences in dyspnea, exercise capacity, physical function, physical activity, and quality of life between an 8-week maintenance program delivered onsite and via tele-rehab at 8-weeks and 4-months post-intervention in patients with Chronic Lung Disease following discharge from traditional onsite outpatient rehabilitation.\n\nParticipants in both intervention groups (onsite and tele-rehab) will undergo a baseline onsite assessment followed by an 8-week supervised exercise intervention either onsite or in a telehealth setting. Control group will receive biweekly check in calls, but no active intervention.",[85,86,87,88,89,90,91,92,26,93],"Copd","COPD Exacerbation","COPD Bronchitis","Emphysema or COPD","Chronic Lung Disease","Pulmonary Fibrosis","Interstitial Lung Disease","Bronchiectasis","Chronic Asthmatic Bronchitis","2024-07-30",{"date":96,"type":31},"2024-08-01",{"date":98,"type":31},"2023-09-01",{"date":100,"type":20},"2026-03-01",{"name":102,"class":38},"MGH Institute of Health Professions"]